Our vision is a world in which the most severe effects of autism do not occur.
Our mission is to detect and mitigate Maternal Autoantibody Related Autism (MARA).
We can detect the likelihood of MARA in a child using a simple blood test in the mother.
What we do
WHY IT MATTERS
MARAbio has developed precision technology to accurately predict the likelihood of MARA in a child through a simple blood test in the mother even before clinical symptoms exist, including prior to pregnancy or as early as birth. Furthermore, our research and development efforts extend from MARA detection to developing specific therapeutic interventions.
By enabling the earliest detection of MARA, care providers can initiate early interventions, tailor approaches and specific strategies for better outcomes.
“It's good to finally have answers...”
How we do it
Our precision technology uses a blood test in women either prior to pregnancy or as early as birth to identify the presence of a distinct cluster of antibodies that lead to MARA. This enables the earliest available assessment, with over 90% predictive accuracy of a positive MARA test in a mom and diagnosis of severe autism in her child, even before clinical symptoms exist.
